It took a while, but healthcare giant Johnson & Johnson (NYSE:JNJ) is once again delivering on its potential as a triple-threat in drugs, devices, and OTC consumer and health products. Strong growth in the drug and devices business is very much welcome, but now the question becomes whether management can lead a similar turnaround in OTC. Although J&J looks to be on the cusp of being a good buy, ongoing outperformance does seem predicated on a more well-rounded growth profile in the coming years.

Forex Broker Guide: Using the right broker is essential when competing in today's forex marketplace.

Once Again a Growth Story
J&J's revenue for the third quarter was only slightly above the average analyst's guess, but organic growth of over 5% is quite a good result in the healthcare sector today. Growth was driven solely by the company's pharmaceutical and devices businesses, where revenue increased more than 11% and 16% respectively. Although the consumer segment was a positive contributor, it did not impress with 1% adjusted revenue growth. Although the profitability numbers require a little explanation, the overall performance was solid. Gross margin did slip over 100 basis points from last year, due in part to ongoing remediation costs in the consumer business and licensing costs in the drug business. Operating income rose 9%, however, as the company did see solid SG&A leverage.

Pharma Back in Black
It has taken several years and a lot of deals (both acquisitions and in-licensing), but J&J's drug business is back to good health. Importantly, it's not just a new drug story - drugs such as Zytiga and Xarelto are certainly contributing to growth, but older drugs such as Remicade, Concerta and Stelara continue to deliver solid performances as well. Although J&J has been getting credit for this improved performance in pharmaceuticals, an argument could be made that the company is still not getting full credit for its pipeline. Like Pfizer (NYSE:PFE) and AstraZeneca (NYSE:AZN), J&J is working on oral immunology drugs, as well as looking to expand its biologics franchise. Moreover, while J&J may not deserve as much attention for its hepatitis C research as Gilead (Nasdaq:GILD) or Abbott (NYSE:ABT), it's hardly an also-ran effort.

Still Some Work to Do in Devices
In contrast to the drug business, some may see J&J's device business lacking in near-term catalysts, despite it's recent positive quarter. Some of this can be tied to macroeconomic issues outside of the company's control - relative to prescription drugs, the co-pays and deductibles for device-based interventions have gotten worse and hospitals have pushed back aggressively on device costs. That said, whatever the reason may be, management needs to focus on keeping this business on a growth track. The company's orthopedic business is looking a little better, but I have to wonder if some of this is a product of turbulence at Stryker (NYSE:SYK). Elsewhere, the surgical business seems soft relative to the recent performance of Covidien (NYSE:COV), and the performance of the diagnostics business is not impressive. Diabetes is also weak, but this is increasingly looking like an industry-wide malaise.

The Bottom Line
The good and bad of J&J is that it's never a pure-play on much of anything; it has been a while since all three business units have really been strong at the same time. In any case, J&J looks like one of the stronger pharmaceutical stories in the space right now, while the device business isn't markedly softer than most other major medical device players such as Medtronic (NYSE:MDT). The last couple of years have been below-trend for J&J. The reason that matters is that a projected free cash flow (FCF) growth rate of 7% might sound too aggressive for a company of its size, but at least 20% of that can be tied to simply getting back to historical levels of free cash flow conversion. In any case, if J&J can continue to post low-to-mid single-digit revenue growth and modest free cash flow conversion improvements, it's not hard to argue for a fair value over $80. That's not massive undervaluation, but when the dividend yield is included, I'd argue it makes this a worthwhile stock to consider for value- and income-oriented investors.

At the time of writing, Stephen D. Simpson did not own any shares in any company mentioned in this article.

Related Articles
  1. Stock Analysis

    3 Resilient Oil Stocks for a Down Market

    Stuck on oil? Take a look at these six stocks—three that present risk vs. three that offer some resiliency.
  2. Economics

    Keep an Eye on These Emerging Economies

    Emerging markets have been hammered lately, but these three countries (and their large and young populations) are worth monitoring.
  3. Stock Analysis

    Is Pepsi (PEP) Still a Safe Bet?

    PepsiCo has long been known as one of the most resilient stocks throughout the broader market. Is this still the case today?
  4. Investing

    The ABCs of Bond ETF Distributions

    How do bond exchange traded fund (ETF) distributions work? It’s a question I get a lot. First, let’s explain what we mean by distributions.
  5. Stock Analysis

    The 5 Best Dividend Stocks in the Healthcare Sector

    Learn about the top five dividend stocks of companies operating in the health care sector that generate substantial cash flows to afford high payouts.
  6. Stock Analysis

    3 Stocks that Are Top Bets for Retirement

    These three stocks are resilient, fundamentally sound and also pay generous dividends.
  7. Investing News

    Are Stocks Cheap Now? Nope. And Here's Why

    Are stocks cheap right now? Be wary of those who are telling you what you want to hear. Here's why.
  8. Investing News

    4 Value Stocks Worth Your Immediate Attention

    Here are four stocks that offer good value and will likely outperform the majority of stocks throughout the broader market over the next several years.
  9. Investing News

    These 3 High-Quality Stocks Are Dividend Royalty

    Here are three resilient, dividend-paying companies that may mitigate some worry in an uncertain investing environment.
  10. Stock Analysis

    An Auto Stock Alternative to Ford and GM

    If you're not sure where Ford and General Motors are going, you might want to look at this auto investment option instead.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!